← All trials
NCT04819100
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Aug 31, 2028
- Completion date
- Nov 30, 2032
- First posted
- Mar 26, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Loxo OncologyLead sponsor
- Eli LillyStudy director
- Eli LillyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.